HBeAg阴性慢性乙型肝炎干扰素治疗的疗效观察

Clinical study of the efficacy of interferon-α therapy for HBeAg-negative chronic hepatitis B patients

目的了解IFN治疗HBeAg阴性慢性乙型肝炎的疗效。方法选择HBeAg阴性慢性乙型肝炎患者50例为治疗组，HBeAg阳性慢性乙型肝炎患者52例为对照组，治疗组及对照组均采用6MU IFN-α隔日一次肌肉注射，疗程48周，观察2组患者治疗前及疗程完成时及之后24周的ALT、HBeAg、HBVDNA、纤维化四项定量指标。结果疗程完成后24周，治疗组36人有效，有效率72％，高于对照组（X^2=5．43，P〈0．05），对照组26人有效，有效率50％；治疗组及对照组肝纤维化四项定量指标治疗前后均下降明显（t=2．365，P〈0．05）。结论6MU IFN-α治疗HBe舷阴性慢性乙型肝炎效果好，较HBeAg阳性慢性乙型肝炎的疗效明显；IFN有显著阻断或延缓慢性乙型肝炎肝纤维化的作用。

Objective To investigate the effect of IFN-α therapy for HBeAg-negative chronic hepatitis B（CHB）. Methods 50 cases of HBeAg-negative CHB patients were selected as treated group, while 52 cases of HBeAg-positive CHB as control group. Both groups received injection of IFN-α at dose of 6 MU every other day for 48 weeks. Levels of alanine aminotransferase, viral markers levels of HBeAg, HBV DNA and the four serum fibrosis markers were analysed before and after treatment and 24 weeks after the course. Results There were 36 eases in treated group and 26 cases in control group who had got obvious therapeutic effects at the end of 24 weeks after treatment. And the rates of efficacy were 72% and 50% separately. The rate of treated group was higher than that of control group（X^2 = 5.43, P 〈 0.05）. The four serum fibrosis markers of the both groups were clearly dropped after treatment （ t = 2.365, P 〈 0.05 ）. Conclusions The tberaputic effects of IFN-α at dose of 6 MU for HBeAg-negative CHB is prior to HBeAg-positive CHB. And IFN-α also have an evident funtion on preventing or delaying hepatic fibrosis in patients with CHB.